Skip to main content

BridgeBio Oncology Therapeutics, Inc.

BBOT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001869105

In the last 90 days, BridgeBio Oncology Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 88 institutions reported holding it in 13F filings for Q3 2026, worth $246.7M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by BridgeBio Oncology Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $184.86 in total
Insiders trading
1
Net value
−$184.86
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for BridgeBio Oncology Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for BridgeBio Oncology Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Cobo MarcPrincipal Accounting Officer13,734Nov 17, 20265
Elmelech IdanCOO & Principal Financial Ofcr14,152Oct 5, 20263
Beltran PedroPresident and CEO43,529Oct 5, 20265
Ben YongChief Med & Dev Officer43,529Oct 5, 20264
Chen BihuaDirector, 10% Owner6,083,221IndirectJul 6, 20262
McCormick FrankDirector–Jun 18, 20261
Bauer JakeDirector–Jun 18, 20261
Kumar NeilDirector–Jun 18, 20261
Tipirneni Praveen P.Director–Jun 18, 20261
Kelleher Raymond J.Director–Jun 18, 20261
Lebowitz Peter FDirector–Jun 18, 20262
Mehra UneekOther: Former Officer22,806May 5, 20262
Wallace Eli M.Chief Executive Officer–Jan 5, 20262
BridgeBio Pharma, Inc.10% Owner14,589,846Oct 16, 20250
BridgeBio Pharma LLC10% Owner14,589,846Oct 16, 20250
Schmid John P.Other: Former Director30,000Aug 11, 20250
McKenna Mark C.Other: Former Director30,000Aug 11, 20250
Tripp CalebChief Financial Officer–Aug 11, 20250
Obradovic NebojsaChief Legal Officer–Aug 11, 20250
Holman Albert A IIIOther: Former Director30,000Aug 11, 20250
Helix Holdings II LLCDirector, 10% Owner509,000IndirectFeb 10, 20250

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 17, 2026 (view filing)4:35 PM ETNov 134 daysCobo MarcPrincipal Accounting OfficerSSale−78$2.37−$184.86−0.6%13.7K after10b5-1
Feb 13, 2024 (view filing)Feb 13Same dayChen BihuaCEO and ChairpersonPPurchaseClass A Ordinary Shares+2.40M$10.00+$24.0MNew position903.6K after3 lots